Stephen C. Yang, MD

Call
Website

Advertisement

Photos

601 N Caroline St Fl 8
Baltimore, MD 21287
Dr. Stephen C. Yang is a professor of surgery and medical oncology at Johns Hopkins University School of Medicine and The Johns Hopkins Hospital. In October 2008 he was named the first recipient of The Arthur B. and Patricia B. Modell Professor in Thoracic Surgery. Dr. Yang is an extreme supporter of medical students, being the only surgeon (amongst 20 chosen from the School of Medicine) for the medical student advisory Colleges system, and is the faculty sponsor for the Surgery Interest Group and the Asian Pacific American Medical Student Association. Dr. Yang graduated from Duke University with a B.A. in Chemistry and received his M.D. degree from the Medical College of Virginia. He completed his general surgery residency at the University of Texas Health Science Center at Houston, and finished his cardiothoracic surgery fellowship at the Medical College of Virginia. He also completed a 3-year thoracic surgical oncology research fellowship at the University of Texas M. D. Anderson Cancer Center. He currently serves on the Postgraduate Affairs, Medical School Admissions, Educational Policy, and Curriculum Reform Committees in the Johns Hopkins School of Medicine. He served on numerous national and international committees for these organizations, and is the Taskforce Chair on the Looking to the Future Residency Scholarships for the Society of Thoracic Surgeons. He is Editor of Practical Reviews in Chest Medicine and guest editor/ reviewer for numerous peer review journals. He is co-editor of the book Current Therapy in Thoracic and Cardiovascular Surgery, edited the esophageal surgical section in the 2nd edition of Atlas of Gastrointestinal Surgery with John Cameron, M.D., and series editor-in-chief of The Early Diagnosis of Cancer also editing the book volume of The Early Diagnosis of Lung Cancer. In 2001, he and his lung transplant team were featured in the ABC series 24/7 and is currently also being followed in the sequel to that series focusing in on resident and medical student teaching. This series as well as other experiences are still shown on the Discovery Channel. The extensive work in preparing an esophageal cancer patient for surgery on the BBC and the Discovery Channel. Dr. Yang's laboratory research interests include using molecular techniques for lung cancer screening and for molecular staging of micrometastasis to predict recurrence following surgical resection. His clinical practice and research covers the breadth of general thoracic surgery in pulmonary and esophageal surgery, video-assisted and robotics thoracic surgery, mediastinal and pleural work, lung volume reduction surgery for emphysema, and work in geriatric thoracic surgery. To support Dr. Yang's research, visit: https://secure.jhu.edu/form/yang
Owner verified
See a problem?

You might also like

Max Kates, MD
Internal medicine practitioners

Max Kates, MD

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009.
Jaishri Blakeley, MD
Internal medicine practitioners

Jaishri Blakeley, MD

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care.
United StatesMarylandBaltimoreStephen C. Yang, MD

Partial Data by Infogroup (c) 2025. All rights reserved.

Yext

Advertisement